OMER - Omeros Corporation
IEX Last Trade
4.21
0.140 3.325%
Share volume: 177,997
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$4.07
0.14
3.44%
Fundamental analysis
42%
Profitability
45%
Dept financing
26%
Liquidity
75%
Performance
34%
Performance
5 Days
-0.71%
1 Month
-19.35%
3 Months
26.81%
6 Months
-7.06%
1 Year
15.34%
2 Year
12.87%
Key data
Stock price
$4.21
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.92 - $5.68
52 WEEK CHANGE
$0.19
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Gregory Demopulos
Region: US
Website: http://www.omeros.com
Employees: 243
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.omeros.com
Employees: 243
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
Recent news